Igari Hidetoshi, Watanabe Akira, Segawa Shunsuke, Suzuki Akiko, Watanabe Mariko, Sakurai Takayuki, Watanabe Masaharu, Tatsumi Koichiro, Nakayama Mikio, Suzuki Kazuo, Sato Takeyuki
Divisions of Control and Treatment of Infectious Diseases, Chiba University Hospital, Chiba, Japan.
Clin Vaccine Immunol. 2012 Oct;19(10):1690-2. doi: 10.1128/CVI.00077-12. Epub 2012 Aug 1.
The immunogenicity of pandemic influenza A H1N1 virus (A/H1pdm) vaccine might be modified by prior seasonal trivalent influenza vaccine (sTIV) administration. We conducted a retrospective analysis of immunogenicity of 243 health care workers (number of sTIV-positive [sTIV(+)] subjects, 216; number of sTIV(-) subjects, 27) by hemagglutination inhibition. There was no significant difference in the ratios of antibody titers of ≥40 (41.2% versus 48.1%; P = 0.49) and fold increases in geometric mean titer (3.8 versus 4.5; P = 0.37). sTIV injected 7 to 10 days prior to A/H1pdm vaccine administration did not interfere with the immunogenicity of the latter.
甲型H1N1大流行性流感病毒（A/H1pdm）疫苗的免疫原性可能会因之前接种季节性三价流感疫苗（sTIV）而改变。我们通过血凝抑制试验对243名医护人员（sTIV阳性[sTIV(+)]受试者216名，sTIV阴性[sTIV(-)]受试者27名）的免疫原性进行了回顾性分析。抗体滴度≥40的比例（41.2%对48.1%；P = 0.49）以及几何平均滴度的增长倍数（3.8对4.5；P = 0.37）均无显著差异。在接种A/H1pdm疫苗前7至10天注射sTIV并不干扰后者的免疫原性。
